Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Impact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Compound Panax Notoginseng Granule;   Drug: Placebo Granule
Sponsors:   Guangdong Provincial Hospital of Traditional Chinese Medicine;   Beijing Genomics Institute
Not yet recruiting - verified June 2017

Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome

Conditions:   Acute Coronary Syndrome;   Percutaneous Coronary Intervention;   Drug-Eluting Stents
Interventions:   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsor:   Thorax Centrum Twente
Completed - verified June 2017

Coronary CT Angiography for Improved Assessment of Suspected Acute Coronary Syndrome

Conditions:   Acute Coronary Syndrome;   Chest Pain
Intervention:   Diagnostic Test: Coronary CT Angiography
Sponsor:   Admir Dedic
Not yet recruiting - verified June 2017

A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered

Condition:   Sickle Cell Disease
Interventions:   Drug: Ticagrelor granule;   Drug: Ticagrelor pediatric tablets;   Drug: Ticagrelor pediatric tablets suspended in water;   Drug: Ticagrelor immediate release (IR) tablets (Commercial tablet)
Sponsors:   AstraZeneca;   Parexel
Active, not recruiting - verified June 2017

Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

Conditions:   Severe Aplastic Anemia;   Hypo-Plastic MDS;   Myelodysplastic Syndrome (MDS)
Intervention:   Biological: CordIn(TM)
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 14, 2017

Provider Perceptions of Neuromuscular Blockade in ARDS

Conditions:   Neuromuscular Blockade;   Acute Respiratory Distress Syndrome
Intervention:   Behavioral: Interview
Sponsors:   University of Pittsburgh;   National Heart, Lung, and Blood Institute (NHLBI)
Enrolling by invitation - verified June 2017

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS

Condition:   ST Elevation Myocardial Infarction
Interventions:   Drug: DLBS1033;   Drug: Placebo;   Drug: Standard therapy
Sponsors:   Dexa Medica Group;   Binawaluya Cardiac Hospital, Jakarta
Recruiting - verified June 2017

Interest of CARE Rule to Exclude the Hypothesis of an Acute Coronary Syndrome Without Bioassay - ICARE

Condition:   Chest Pain
Intervention:   Other: CARE Rule
Sponsor:   University Hospital, Angers
Recruiting - verified June 2017

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Conditions:   B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2017

Programme of Lifestyle Intervention in Families for Cardiovascular Risk Reduction

Condition:   Coronary Heart Disease
Intervention:   Behavioral: Integrated cardiovascular disease risk management.
Sponsors:   Public Health Foundation of India;   Sree Chitra Tirunal Institute for Medical Sciences & Technology
Active, not recruiting - verified June 2017

Transfusion-Associated Circulatory Overload Best Eliminated With Lasix

Condition:   Transfusion-associated Circulatory Overload
Interventions:   Drug: Furosemide;   Drug: Normal Saline
Sponsors:   Sunnybrook Health Sciences Centre;   University Health Network, Toronto;   Canadian Blood Services
Completed - verified October 2016

A Randomised Controlled Trial of High-Flow Nasal Oxygen Versus Standard Oxygen Therapy in Critically Ill Immunocompromised Patients

Condition:   Acute Respiratory Failure
Interventions:   Procedure: standard oxygen;   Procedure: HFNO
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified June 2017

"Me and My Heart" Study

Condition:   Acute Coronary Syndrome
Interventions:   Device: Active group with MEMS;   Device: Active group without MEMS;   Device: Control group with MEMS;   Device: Control group without MEMS
Sponsor:   AstraZeneca
Recruiting - verified June 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified June 2017

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

Conditions:   Arterial Occlusive Diseases;   Coronary Artery Disease;   Coronary Disease;   Arteriosclerosis;   Heart Diseases;   Myocardial Ischemia;   Vascular Diseases;   Acute Coronary Syndrome
Interventions:   Drug: PZ-128;   Drug: Placebo
Sponsors:   Tufts Medical Center;   National Heart, Lung, and Blood Institute (NHLBI);   RTI International;   Inova Fairfax Hospital;   University of Massachusetts, Worcester
Recruiting - verified June 2017

Biomarkers, Blood Pressure, BIS: Risk Stratification/Management of Patients at Cardiac Risk in Major Noncardiac Surgery

Conditions:   Hypotension;   Postoperative Complications;   Acute Coronary Syndrome;   Heart Failure;   Coronary Occlusion;   Stroke;   Acute Kidney Injury;   Renal Insufficiency, Chronic;   Death
Interventions:   Drug: Liberal blood pressure management;   Drug: Tight blood pressure management
Sponsor:   Miodrag Filipovic, Prof. Dr. med.
Recruiting - verified June 2017

Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention

Conditions:   Acute Coronary Syndrome;   Cardiovascular Diseases
Intervention:   Genetic: CYP2C19 genotyping
Sponsor:   University of Pennsylvania
Active, not recruiting - verified June 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified June 2017

Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes

Condition:   Acute Coronary Syndrome
Interventions:   Drug: ticagrelor;   Drug: clopidogrel
Sponsors:   Seung-Jung Park;   AstraZeneca;   Roche Pharma AG;   KBM pharm
Completed - verified June 2017

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified June 2017

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2017

Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease

Condition:   Sickle Cell Disease
Intervention:   Drug: Hydroxyurea
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 14, 2017

Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management

Conditions:   Acute Coronary Syndrome;   Myocardial Ischemia;   Heart Diseases;   Cardiovascular Diseases;   Angina Pectoris
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Active, not recruiting - verified June 2017

Prehospital Antibiotics Against Sepsis Trial

Conditions:   Sepsis;   Severe Sepsis;   Septic Shock
Intervention:   Drug: Ceftriaxone 2000 mg
Sponsors:   VU University Medical Center;   Stichting Nuts Ohra;   Nederlandse Internisten Vereniging ( Dutch Association of Internists)
Completed - verified June 2017

Physiological Study of Low-frequency HFO/HFO-TGI and High-frequency HFO

Conditions:   Acute Respiratory Distress Syndrome;   Acute Cor Pulmonale
Intervention:   Other: High Frequency Oscillation
Sponsor:   University of Athens
Completed - verified June 2017

Treosulfan, Fludarabine Phosphate, and Total Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation;   Drug: Treosulfan
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified June 2017

Efficacy Evaluation of the HEART Pathway in Emergency Department Patients With Acute Chest Pain

Conditions:   Acute Coronary Syndrome;   Chest Pain
Intervention:   Other: HEART Pathway
Sponsors:   Wake Forest University Health Sciences;   American Heart Association
Active, not recruiting - verified June 2017

Transplants With Unlicensed Preserved Cord Blood

Conditions:   Myelodysplastic Syndrome (MDS);   Hematologic Neoplasms;   Hematologic Diseases;   Severe Aplastic Anemia
Intervention:   Procedure: Cord Blood Transplant
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 15, 2017

Karolinska Cardiorenal Theme-centre and StockholmHeartbank

Conditions:   Chronic Kidney Disease;   Chronic Renal Failure;   Acute Coronary Syndrome;   Ischemic Heart Disease;   Myocardial Infarction
Intervention:  
Sponsors:   Danderyd Hospital;   Stockholm County Council, Sweden;   Karolinska Institutet;   Uppsala University;   Lund University;   Stockholm South General Hospital;   Karolinska University Hospital
Recruiting - verified June 2017

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome

Conditions:   Myelodysplastic Syndrome (MDS);   Severe Aplastic Anemia (SAA)
Interventions:   Other: Umbilical Cord Blood;   Other: Haploidentical Stem Cells;   Device: Miltenvi CliniMACs CD34 Reagent System
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 1, 2017

Experimental Bone Marrow Transplant Protocol

Conditions:   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Acute Myelocytic Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorders
Intervention:   Device: Isolex 300i Stem Cell Selection
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 14, 2017

The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers

Conditions:   Chronic Lymphocytic Leukemia;   Graft vs Host Disease;   Hematologic Neoplasm;   Multiple Myeloma;   Myelodysplastic Syndrome
Intervention:   Device: Isolex 300i plus MoAbs
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 13, 2017